Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
October 13 2022 - 7:30AM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the
appointment of Adora Ndu, Pharm.D., J.D. to its Board of Directors.
Dr. Ndu is a biopharma executive with more than 15 years of
experience in regulatory affairs and clinical development.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221013005276/en/
Dr. Adora Ndu. (Photo: Business Wire)
“We are pleased to welcome Dr. Ndu to Acadia’s Board,” said
Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia’s Board of
Directors. “Dr. Ndu’s significant regulatory and clinical
development experience, combined with her extensive background in
rare disease nicely complements the skill sets of our current
membership. Her expertise will be invaluable as we continue to
pursue our strategic initiatives in disorders affecting the central
nervous system, particularly as the company prepares to launch its
second commercial product, trofinetide, for the treatment of Rett
syndrome.”
“I am honored to join Acadia’s Board of Directors. I look
forward to collaborating with its members alongside Acadia’s
talented management team as they develop and commercialize
innovative new therapies addressing high unmet needs in the field
of CNS,” said Dr. Ndu.
Since 2022, Dr. Ndu has served as the Chief Regulatory Affairs
Officer of BridgeBio. Previously, she was the Group Vice President,
Head of Worldwide Research and Development Strategy, Scientific
Collaborations and Policy at BioMarin Pharmaceutical. She brings
over 15 years of complementary experience in drug development and
regulatory affairs. Dr. Ndu has spent eight years in various
leadership roles in the biopharmaceutical sector. Her expertise
includes regulatory strategy, patient engagement, prescription drug
promotion, and policy for U.S. and international markets.
Additionally, Dr. Ndu spent eight years at the U.S. Food and Drug
Administration, Center for Drug Evaluation and Research, where she
progressed in leadership serving most recently as Director for the
Division of Medical Policy Development and Commander in the U.S.
Public Health Service. She has been involved in the registrations
of multiple products globally and is a respected thought leader in
regulatory science, having played a significant role in developing
and evaluating guidance, as well as shaping regulatory policy. Dr.
Ndu currently serves on the board of DBV Technologies. Dr. Ndu
received her doctorate in pharmacy from Howard University’s College
of Pharmacy and a law degree from the University of Maryland.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our clinical-stage development
efforts are focused on treating the negative symptoms of
schizophrenia, Rett syndrome and neuropsychiatric symptoms in
central nervous system disorders. For more information, visit us at
www.acadia.com and follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221013005276/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024